|
Prospective evaluation of current RAS mutation testing practices in newly diagnosed metastatic colorectal cancer: Middle East and North Africa Registry (MORE-RAS) Study. |
| |
|
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Roche |
Speakers' Bureau - Amgen; Bayer; Ipsen; Roche |
Expert Testimony - Amgen; Bayer; Ipsen; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|